Combined growth hormone-releasing hormone and growth hormone-releasing peptide-6 test for the evaluation of growth hormone secretion in children with growth hormone deficiency and growth hormone neurosecretory dysfunction.

Spiliotis BE, Papadimitriou DT, Alexandrides TK, Karystianos C, Nikiforidis G, Vassilakos P, Beratis NG, Casanueva FF

Hormone research5 Sept 2008Cited by 2 (Europe PMC)

PMID18772594DOI10.1159/000151593PepBankPUB-18772594

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone9

In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking GHRP-6.

01HumanNot a test of GHRP-6 aloneNon-randomized trialActivity measurement
In children, six nonresponders to GHRH plus GHRP‑6 had lower peak GH than controls and responding patients.
In plain wordsChildren who did not respond to GHRH plus GHRP‑6 had lower peak GH than controls and responding patients.
Peptide
GHRP-6
Outcome
DecreasePeak GH in nonresponders
Study
n: not reported in source
Comparator
Controls and responding patients
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Measurements
Peak GH
20.7 microg/l
Nonresponders
Peak GH range
7.8 to 31.8 microg/l
Nonresponders
Source sentences
Summary
Six were nonresponders to the combined test, with significantly lower peak GH 20.7 (7.8-31.8) than C and the rest of the patients (responders).
1 context sentence(design, population, supporting numbers)
Summary · context
35 children with GH <10 microg/l after levo-dopa/clonidine (GHD), 15 with normal provocative tests but abnormal 24-hour spontaneous GH secretion (GHND), and 20 controls (C) were given 1 microg/kg of GHRH and GHRP-6 i.v. and GH (microg/l) was measured at -15, 0, 5, 10, 15, 30, 45 and 60 min.
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-1877259401
02HumanNot a test of GHRP-6 aloneNon-randomized trialActivity measurement
After GHRH plus GHRP‑6, prepubertal children with GH deficiency had peak GH similar to prepubertal controls.
In plain wordsAfter GHRH plus GHRP‑6, prepubertal children with GH deficiency had peak GH similar to controls.
Peptide
GHRP-6
Outcome
No significant changePrepubertal peak GH: GHD versus controls
Study
n: not reported in source
Comparator
Prepubertal controls
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Measurements
Peak GH
202 microg/l
Prepubertal GHD
Peak GH
167 microg/l
Prepubertal controls
Source sentences
Summary
Peak GH was similar between prepubertal (PP) controls 167 +/- 88, GHD 202 +/- 110 and GHND 155 +/- 83.
1 context sentence(design, population, supporting numbers)
Summary · context
35 children with GH <10 microg/l after levo-dopa/clonidine (GHD), 15 with normal provocative tests but abnormal 24-hour spontaneous GH secretion (GHND), and 20 controls (C) were given 1 microg/kg of GHRH and GHRP-6 i.v. and GH (microg/l) was measured at -15, 0, 5, 10, 15, 30, 45 and 60 min.
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-1877259402
03HumanNot a test of GHRP-6 aloneNon-randomized trialActivity measurement
After GHRH plus GHRP‑6, prepubertal children with GH neurosecretory dysfunction had peak GH similar to prepubertal controls.
In plain wordsAfter GHRH plus GHRP‑6, prepubertal children with GH neurosecretory dysfunction had peak GH similar to controls.
Peptide
GHRP-6
Outcome
No significant changePrepubertal peak GH: GHND versus controls
Study
n: not reported in source
Comparator
Prepubertal controls
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Measurements
Peak GH
155 microg/l
Prepubertal GHND
Peak GH
167 microg/l
Prepubertal controls
Source sentences
Summary
Peak GH was similar between prepubertal (PP) controls 167 +/- 88, GHD 202 +/- 110 and GHND 155 +/- 83.
1 context sentence(design, population, supporting numbers)
Summary · context
35 children with GH <10 microg/l after levo-dopa/clonidine (GHD), 15 with normal provocative tests but abnormal 24-hour spontaneous GH secretion (GHND), and 20 controls (C) were given 1 microg/kg of GHRH and GHRP-6 i.v. and GH (microg/l) was measured at -15, 0, 5, 10, 15, 30, 45 and 60 min.
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-1877259403
04HumanNot a test of GHRP-6 aloneNon-randomized trialActivity measurement
After GHRH plus GHRP‑6, peak GH was similar in prepubertal children with GH deficiency and GH neurosecretory dysfunction.
In plain wordsAfter GHRH plus GHRP‑6, prepubertal children with GH deficiency and GH neurosecretory dysfunction had similar peak GH.
Peptide
GHRP-6
Outcome
No significant changePrepubertal peak GH: GHD versus GHND
Study
n: not reported in source
Comparator
Prepubertal GHND
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Measurements
Peak GH
202 microg/l
Prepubertal GHD
Peak GH
155 microg/l
Prepubertal GHND
Source sentences
Summary
Peak GH was similar between prepubertal (PP) controls 167 +/- 88, GHD 202 +/- 110 and GHND 155 +/- 83.
1 context sentence(design, population, supporting numbers)
Summary · context
35 children with GH <10 microg/l after levo-dopa/clonidine (GHD), 15 with normal provocative tests but abnormal 24-hour spontaneous GH secretion (GHND), and 20 controls (C) were given 1 microg/kg of GHRH and GHRP-6 i.v. and GH (microg/l) was measured at -15, 0, 5, 10, 15, 30, 45 and 60 min.
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-1877259404
05HumanNot a test of GHRP-6 aloneNon-randomized trialActivity measurement
After GHRH plus GHRP‑6, pubertal children with GH deficiency had lower peak GH than pubertal controls.
In plain wordsAfter GHRH plus GHRP‑6, pubertal children with GH deficiency had lower peak GH than controls.
Peptide
GHRP-6
Outcome
DecreasePubertal peak GH: GHD versus controls
Study
n: not reported in source
Comparator
Pubertal controls
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Measurements
Peak GH
203 microg/l
Pubertal GHD
Peak GH
328 microg/l
Pubertal controls
Source sentences
Summary
Pubertal (P) controls had higher peak GH 328 +/- 149 than P-GHD 203 +/- 105 and P-GHND 186 +/- 105.
1 context sentence(design, population, supporting numbers)
Summary · context
35 children with GH <10 microg/l after levo-dopa/clonidine (GHD), 15 with normal provocative tests but abnormal 24-hour spontaneous GH secretion (GHND), and 20 controls (C) were given 1 microg/kg of GHRH and GHRP-6 i.v. and GH (microg/l) was measured at -15, 0, 5, 10, 15, 30, 45 and 60 min.
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-1877259405
06HumanNot a test of GHRP-6 aloneNon-randomized trialActivity measurement
After GHRH plus GHRP‑6, pubertal children with GH neurosecretory dysfunction had lower peak GH than pubertal controls.
In plain wordsAfter GHRH plus GHRP‑6, pubertal children with GH neurosecretory dysfunction had lower peak GH than controls.
Peptide
GHRP-6
Outcome
DecreasePubertal peak GH: GHND versus controls
Study
n: not reported in source
Comparator
Pubertal controls
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Measurements
Peak GH
186 microg/l
Pubertal GHND
Peak GH
328 microg/l
Pubertal controls
Source sentences
Summary
Pubertal (P) controls had higher peak GH 328 +/- 149 than P-GHD 203 +/- 105 and P-GHND 186 +/- 105.
1 context sentence(design, population, supporting numbers)
Summary · context
35 children with GH <10 microg/l after levo-dopa/clonidine (GHD), 15 with normal provocative tests but abnormal 24-hour spontaneous GH secretion (GHND), and 20 controls (C) were given 1 microg/kg of GHRH and GHRP-6 i.v. and GH (microg/l) was measured at -15, 0, 5, 10, 15, 30, 45 and 60 min.
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-1877259406
07HumanNot a test of GHRP-6 aloneNon-randomized trialActivity measurement
After GHRH plus GHRP‑6, pubertal controls had higher peak GH than prepubertal controls.
In plain wordsAfter GHRH plus GHRP‑6, pubertal controls had higher peak GH than prepubertal controls.
Peptide
GHRP-6
Outcome
IncreasePeak GH by puberty in controls
Study
n: not reported in source
Comparator
Prepubertal controls
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Source sentences
Summary
While P-C had higher peak GH than PP-C, PP and P children had similar responses within the GHD and GHND groups.
1 context sentence(design, population, supporting numbers)
Summary · context
35 children with GH <10 microg/l after levo-dopa/clonidine (GHD), 15 with normal provocative tests but abnormal 24-hour spontaneous GH secretion (GHND), and 20 controls (C) were given 1 microg/kg of GHRH and GHRP-6 i.v. and GH (microg/l) was measured at -15, 0, 5, 10, 15, 30, 45 and 60 min.
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-1877259407
08HumanNot a test of GHRP-6 aloneNon-randomized trialActivity measurement
After GHRH plus GHRP‑6, pubertal and prepubertal children with GH deficiency had similar responses.
In plain wordsAfter GHRH plus GHRP‑6, children with GH deficiency had similar responses before and during puberty.
Peptide
GHRP-6
Outcome
No significant changePeak GH by puberty in GHD
Study
n: not reported in source
Comparator
Prepubertal children with GHD
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Source sentences
Summary
While P-C had higher peak GH than PP-C, PP and P children had similar responses within the GHD and GHND groups.
1 context sentence(design, population, supporting numbers)
Summary · context
35 children with GH <10 microg/l after levo-dopa/clonidine (GHD), 15 with normal provocative tests but abnormal 24-hour spontaneous GH secretion (GHND), and 20 controls (C) were given 1 microg/kg of GHRH and GHRP-6 i.v. and GH (microg/l) was measured at -15, 0, 5, 10, 15, 30, 45 and 60 min.
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-1877259408
09HumanNot a test of GHRP-6 aloneNon-randomized trialActivity measurement
After GHRH plus GHRP‑6, pubertal and prepubertal children with GH neurosecretory dysfunction had similar responses.
In plain wordsAfter GHRH plus GHRP‑6, children with GH neurosecretory dysfunction had similar responses before and during puberty.
Peptide
GHRP-6
Outcome
No significant changePeak GH by puberty in GHND
Study
n: not reported in source
Comparator
Prepubertal children with GHND
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Source sentences
Summary
While P-C had higher peak GH than PP-C, PP and P children had similar responses within the GHD and GHND groups.
1 context sentence(design, population, supporting numbers)
Summary · context
35 children with GH <10 microg/l after levo-dopa/clonidine (GHD), 15 with normal provocative tests but abnormal 24-hour spontaneous GH secretion (GHND), and 20 controls (C) were given 1 microg/kg of GHRH and GHRP-6 i.v. and GH (microg/l) was measured at -15, 0, 5, 10, 15, 30, 45 and 60 min.
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-1877259409

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
21 Oct 2026, 15:58 UTC
Study results updated
Version 1
9 Oct 2026, 03:13 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.